Incidência do míldio em cebola sob adubação mineral e orgânica.

Analisou-se a relação entre adubação mineral e orgânica sobre a incidência de míldio (Peronospora destructor) em cebola (Allium cepa). O trabalho constituiu-se de dois experimentos localizados em Ituporanga, conduzidos entre agosto e dezembro de 1998. O experimento 1, com fontes orgânicas, constou dos tratamentos: esterco de suínos, esterco de aves, composto, esterco de peru e húmus, na dosagem de 75 kg/ha de N; esterco de suínos, na dosagem de 37,5 kg/ha de N; adubação mineral, 30-120-60 kg/ha de N-P2O5-K2O; 60-240-120 kg/ha de N-P2O5-K2O e testemunha sem adubação. O experimento 2 constou dos tratamentos: fontes minerais, 30-120-60 kg/ha de N-P2O5-K2O; 90-360-180 kg/ha de N-P2O5-K2O; 75 kg/ha de N; 225 kg/ha de N; 80 kg/ha de P2O5; 240 kg/ha de P2O5; 60 kg/ha de K2O; 180 kg/ha de K2O; esterco de suínos + fosfato natural, em três combinações, 7,9+0,1, 15,7+0,2 e 47,2+0,6 t/ha, respectivamente; testemunha sem adubação. Não houve diferença entre as fontes mineral e orgânica sobre a incidência de míldio. A relação entre nutrientes e doença foi variável entre datas de amostragem e distinta para fontes minerais e orgânicas

Systematic Review of Medicine-Related Problems in Adult Patients with Atrial Fibrillation on Direct Oral Anticoagulants

New oral anticoagulant agents continue to emerge on the market and their safety requires assessment to provide evidence of their suitability for clinical use. There-fore, we searched standard databases to summarize the English language literature on medicine-related problems (MRPs) of direct oral anticoagulants DOACs (dabigtran, rivaroxban, apixban, and edoxban) in the treatment of adults with atri-al fibrillation. Electronic databases including Medline, Embase, International Pharmaceutical Abstract (IPA), Scopus, CINAHL, the Web of Science and Cochrane were searched from 2008 through 2016 for original articles. Studies pub-lished in English reporting MRPs of DOACs in adult patients with AF were in-cluded. Seventeen studies were identified using standardized protocols, and two reviewers serially abstracted data from each article. Most articles were inconclusive on major safety end points including major bleeding. Data on major safety end points were combined with efficacy. Most studies inconsistently reported adverse drug reactions and not adverse events or medication error, and no definitions were consistent across studies. Some harmful drug effects were not assessed in studies and may have been overlooked. Little evidence is provided on MRPs of DOACs in patients with AF and, therefore, further studies are needed to establish the safety of DOACs in real-life clinical practice